Clovis Oncology, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2016-11-03: Form 8-K; Period of report 2016-11-03; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2016-10-04: Form 8-K; Period of report 2016-10-03; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2016-09-08: Form 8-K; Period of report 2016-09-08; Description 8.01 Other Events; Details 8.01.
- 2016-08-30: Form 8-K; Period of report 2016-08-30; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2016-11-03 | 8-K | 2016-11-03 | 2.02 Results of Operations and Financial Condition | 2.02 On November 3, 2016, Clovis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2016. | a51453638.htm |
| 2016-10-04 | 8-K | 2016-10-03 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d112272d8k.htm |
| 2016-09-08 | 8-K | 2016-09-08 | 8.01 Other Events | 8.01 The Food and Drug Administration (“FDA”) has notified Clovis Oncology, Inc. (the “Company”) that FDA is not currently planning to hold an advisory committee meeting to discuss the Company’s New Drug Application for rucaparib. | d234230d8k.htm |
| 2016-08-30 | 8-K | 2016-08-30 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d248592d8k.htm |
| 2016-08-08 | 8-K | 2016-08-08 | 2.02 Results of Operations and Financial Condition | 2.02 On August 8, 2016, Clovis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2016. | a51398105.htm |
| 2016-06-10 | 8-K | 2016-06-09 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 The Annual Meeting of Shareholders (the “Annual Meeting”) of Clovis Oncology, Inc. (the “Company”) was held on June 9, 2016. | d27633d8k.htm |
| 2016-05-05 | 8-K | 2016-05-05 | 2.02 Results of Operations and Financial Condition | 2.02 On May 5, 2016, Clovis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2016. | a51336599.htm |
| 2016-04-01 | 8-K | 2016-03-31 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 Effective as of March 31, 2016, upon the previously announced resignation of Erle T. Mast as the Chief Financial Officer of Clovis Oncology, Inc. (the “Company”), Daniel W. Muehl, the Company’s current Vice President of Finance, has been appointed as the Company’s principal financial officer and principal accounting officer. | d168574d8k.htm |
| 2016-02-25 | 8-K | 2016-02-25 | 2.02 Results of Operations and Financial Condition | 2.02 On February 25, 2016, Clovis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and year ended December 31, 2015. | a51288164.htm |
| 2016-01-25 | 8-K | 2016-01-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 25, 2016, Clovis Oncology, Inc. (the “Company”) announced that Steven L. Hoerter has notified the Company that he resigned from his position as Chief Commercial Officer of the Company. | d50938d8k.htm |